Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment
The prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to be 25-30% of the population, and is the most common cause of elevated liver enzymes in Korea. NAFLD is a “hot potato” for pharmaceutical companies. Many clinical trials are underway to develop a first-in-class drug to treat...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Association for the Study of the Liver
2016-09-01
|
Series: | Clinical and Molecular Hepatology |
Subjects: | |
Online Access: | http://e-cmh.org/upload/pdf/cmh-2016-0049.pdf |
id |
doaj-d36e46ca34474964bf51d5f751b78439 |
---|---|
record_format |
Article |
spelling |
doaj-d36e46ca34474964bf51d5f751b784392020-11-24T22:32:27ZengKorean Association for the Study of the LiverClinical and Molecular Hepatology2287-27282287-285X2016-09-0122332733510.3350/cmh.2016.00491310Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatmentHyunwoo Oh0Dae Won Jun1Waqar K Saeed2Mindie H Nguyen3 Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, USAThe prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to be 25-30% of the population, and is the most common cause of elevated liver enzymes in Korea. NAFLD is a “hot potato” for pharmaceutical companies. Many clinical trials are underway to develop a first-in-class drug to treat NAFLD. However, there are several challenging issues regarding the diagnosis of NAFLD. Currently, liver biopsy is the gold standard method for the diagnosis of NAFLD and steatohepatitis. Ideally, globally recognized standards for histological diagnosis and methods to optimize observer agreement on biopsy interpretation should be developed. Liver biopsy is the best method rather than a perfect one. Recently, multi-parametric magnetic resonance imagery can estimate the amount of intrahepatic fat successfully and is widely used in clinical trials. But no diagnostic method can discriminate between steatohepatitis and simple steatosis. The other unresolved issue in regard to NAFLD is the absence of satisfactory treatment options. Vitamin E and obeticholic acid have shown protective effects in randomized controlled trials, but this drug has not been approved for use in Korea. This study will provide a description of diagnostic methods and treatments that are currently recommended for NAFLD.http://e-cmh.org/upload/pdf/cmh-2016-0049.pdfNon-alcoholic fatty liverDiagnosisTreatment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hyunwoo Oh Dae Won Jun Waqar K Saeed Mindie H Nguyen |
spellingShingle |
Hyunwoo Oh Dae Won Jun Waqar K Saeed Mindie H Nguyen Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment Clinical and Molecular Hepatology Non-alcoholic fatty liver Diagnosis Treatment |
author_facet |
Hyunwoo Oh Dae Won Jun Waqar K Saeed Mindie H Nguyen |
author_sort |
Hyunwoo Oh |
title |
Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment |
title_short |
Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment |
title_full |
Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment |
title_fullStr |
Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment |
title_full_unstemmed |
Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment |
title_sort |
non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment |
publisher |
Korean Association for the Study of the Liver |
series |
Clinical and Molecular Hepatology |
issn |
2287-2728 2287-285X |
publishDate |
2016-09-01 |
description |
The prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to be 25-30% of the population, and is the most common cause of elevated liver enzymes in Korea. NAFLD is a “hot potato” for pharmaceutical companies. Many clinical trials are underway to develop a first-in-class drug to treat NAFLD. However, there are several challenging issues regarding the diagnosis of NAFLD. Currently, liver biopsy is the gold standard method for the diagnosis of NAFLD and steatohepatitis. Ideally, globally recognized standards for histological diagnosis and methods to optimize observer agreement on biopsy interpretation should be developed. Liver biopsy is the best method rather than a perfect one. Recently, multi-parametric magnetic resonance imagery can estimate the amount of intrahepatic fat successfully and is widely used in clinical trials. But no diagnostic method can discriminate between steatohepatitis and simple steatosis. The other unresolved issue in regard to NAFLD is the absence of satisfactory treatment options. Vitamin E and obeticholic acid have shown protective effects in randomized controlled trials, but this drug has not been approved for use in Korea. This study will provide a description of diagnostic methods and treatments that are currently recommended for NAFLD. |
topic |
Non-alcoholic fatty liver Diagnosis Treatment |
url |
http://e-cmh.org/upload/pdf/cmh-2016-0049.pdf |
work_keys_str_mv |
AT hyunwoooh nonalcoholicfattyliverdiseasesupdateonthechallengeofdiagnosisandtreatment AT daewonjun nonalcoholicfattyliverdiseasesupdateonthechallengeofdiagnosisandtreatment AT waqarksaeed nonalcoholicfattyliverdiseasesupdateonthechallengeofdiagnosisandtreatment AT mindiehnguyen nonalcoholicfattyliverdiseasesupdateonthechallengeofdiagnosisandtreatment |
_version_ |
1725733871089090560 |